Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2006

View Archived Issues

RhuDex preclinical activity, human pharmacokinetics reported

Neramexane potentiates the efficacy of antidepressants

Benefits of add-on niacin therapy demonstrated in hypercholesterolemia

Activity of RAD-001 and depot octreotide explored in neuroendocrine tumors

Preliminary phase II results show activity of ZD-6474 in medullary thyroid carcinoma

Rigel present a new class of antimitotic agents for cancer therapy

F-15845: a new agent for cardiac ischemia

MediGene and German Cancer Research Center cooperate in ovarian cancer

Statement from TeGenero: Insolvency proceedings were initiated

EMEA validates Iplex submission

Aradigm and Novo Nordisk restructure agreement

Salix files for pediatric exclusivity of Colazal

Promising in vivo results of Pluristem's adjuvant cell therapy product PLX-1

Baxter studies Vero-cell based H5N1 pandemic influenza vaccine in phase I/II trial

Abbott and AstraZeneca to develop fibrate and statin combination treatment

First collaborative compound from Actelion and Merck renin alliance enters clinic

Johnson & Johnson to acquire Pfizer Consumer Healthcare

ISIS-301012 q.o.w. reduces LDL-C and apoB in subjects with mild hypercholesterolemia

Recent patents report new treatment strategies for respiratory diseases

Recent patents describe new therapeutic agents for depression, anxiety, etc.

NDA filing for T-Pred in inflammatory ocular conditions

Valera files for approval of Supprelin-LA in central precocious puberty

Tentative approval for generic three-in-one antiretroviral product

IL-1 Trap demonstrates preliminary efficacy in systemic juvenile idiopathic arthritis

New results of phase I/II studies on tgAAC94 from Targeted Genetics

Further data on IC-31's ability to increase efficacy of TB vaccine Ag85B-ESAT-6

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...